GROWTH+Onco


GROWTH+Onco is a propriety oncology-based product that focuses to provide deep and consequential insights on solid tumors, as well as hematological malignancies, driven by deep, dived data assessment providing cognizance about overall tumor market.

DON’T JUST TRACK DEVELOPMENTSDISCUSS THEM WITH CANCER EXPERTS GLOBALLY

GROWTH+Onco is a propriety subscription based intelbook that offers comprehensive and actionable intelligence and expert insights on solid tumours as well as haematological malignancies. Growth+Onco covers 30 different types of tumours




Track & Comprehend

Exhaustive tumour landscape

Growth+Onco collects cancer landscape data globally from traditional sources. However, we also use GRG’s GrowthMIX approach to capture the most qualitative expert insights making the exercise very exhaustive

Interview Experts

Globally and discuss key topics

Growth+Onco connects the subscribers to cancer experts across the world. Talk to them on phone, video call or an online survey. Our clients speak with researchers, market experts and market access professionals to discuss key topics of relevance.

Customize Intel book

Based upon your requirement

Growth+Onco also enables subscribers to customize insights based upon their requirements with subscription.




Free update

Every 6 months

Growth+Onco also enables subscribers to request a complete report update once every six months with their subscription plans only.

Add-on research

Options available within subscriptions

GRG’s analyst team also work with clients on adding extra insights up to depending upon the type of their subscription.

Conference coverage

Globally for comprehensive subscribers

Growth+Onco also enables subscribers to track medical communication at key conferences customized to their needs.

Growth+Onco also connects subscribers to cancer experts across the world to discuss key topics of relevance. Our clients speak with researchers, market experts and market access professionals across the world as part of their subscriptions.

Growth+Onco also enables subscribers to custom insights based upon their requirements. GRG’s analyst team also work with clients on adding extra insights depending upon the type of their subscription.

The significance of this report not only lies for the clients having a steady presence in the tumor space but also for the clients which are yet to make a mark in the tumor space with a clear vision and strategy in place.

The insights in the report will feed-into the key decision- making the process and enable the development of a futuristic strategy/projects.

Thus, the report is helpful –

  • To stay updated with all the recent developments in the tumor space.
  • To design diseases area strategy to assess any business development opportunities.
  • To design the asset profile, which will ultimately support in building strong oncology pipeline.
  • To support product development via strategy-based recommendation on differential potential of emerging candidate.
  • To train internal resources, as this is a knowledge book which will be like a mini encyclopedia for the tumor space.

Disease Landscape & Epidemiology

  • Disease overview including risk factors, diagnosis, symptoms, pathophysiology & staging or classification
  • Assess unmet needs & corresponding opportunities
  • Epidemiology includes incidence, prevalence, mortality, yearly rates of incidence/ prevalence (1,2 or 5-years) and 5-yr survival rate of the respective tumor in US, EU5, China and Japan. (May include other countries, based on the client requirement)

Current Treatment Landscape

  • Current treatment algorithm
  • Current treatment benchmarks
  • Biomarker segmentation and corresponding approval
  • Approved treatment distribution as per the line of therapy
  • Launches of approved therapies
  • Patent expires of approved therapies

Emerging Treatment Landscape and Competition Landscape

  • Emerging MoAs and Biomarker-driven Segments
  • Emerging Treatment Algorithm
  • Potential Gamechangers & their Estimated Launch Timeline
  • Clinical Hurdles and Entry Barriers
  • Required Efficacy Thresholds and Endpoints
  • Strategy based recommendation on differential potential of emerging candidate

Clinical Trial Analysis

  • Trial profiles of key Competitors including the following information
  • Trial details including patient population, Biomarker segmentation (if any), Trial design, Start date, end date
  • Treatment details including arms, Primary and secondary end points, Dose and dosage form,
  • Results – efficacy and safety results
  • List of Trial failures
  • Acquire not only the basic and essential information about the tumor, but also a detailed description around many fundamental data elements like key gamechangers, emerging treatment landscape etc. that will aid in planning key clinical and commercial developments and BD&L decisions.
  • Stay updated with all the prevailing dynamics of the tumor world.
  • Obtain comprehensive form of all the information collected through in-depth research and the insights drawn from data analysis of the facts and figures gathered through secondary and primary market research (enriched with expert insights around the globe* yielding the overview of global perspective).
  • Procure all the data in one consolidated report and avoid referring to the multiple sources and citations
  • The significance of this report not only lies for the clients having a steady presence in the tumor space but also for the clients which are yet to make a mark in the tumor space with a clear vision and strategy in place.
  • The insights in the report will feed-into the key decision- making process and enable the development of a futuristic strategy/projects.
  • Thus, the report is helpful
      1. To stay updated with all the recent developments in the tumor space

      2. To design diseases area strategy to assess any business development opportunities

      3. To design the asset profile, which will ultimately support in building strong oncology pipeline

      4. To support product development via strategy-based recommendation on differential potential of emerging candidate

      5. To train internal resources, as this is a knowledge book which will be like a mini encyclopedia for the tumor space

Cancer Coverage


Solid Tumours Haematological Malignancies
GI Tumours GU Tumors Women’s Cancer Lung Cancer Other Solid tumors Leukemia Lymphoma Other Heme Tumor
Gastric Cancer Bladder Cancer Breast Cancer (Incl. TNBC, HER2 neg HR+ and HER2 positive breast Cancer) NSCLC Melanoma AML NHL (indolent & aggressive) Multiple Myeloma
Esophageal Cancer Renal Cancer Ovarian Cancer SCLC SCCHN CML Hodgkin’s Lymphoma MDS
Hepatocellular Carcinoma Prostate Cancer Mesothelioma CLL Myelofibrosis
Pancreatic cancer
Gall Bladder Cancer
Colorectal Cancer

To know about various product pack Click here

GRGs Panel of Oncology Experts (Few example profiles)Our global tumour experts includes a wide range of researchers, investigators and oncologists, business professionals and market access professionals


Dr. R.J Salmon

Former Head of Surgery, Institut Curie

25+ years experience in oncology research
Interest areas includes Breast Cancer, Radiation Therapy

Dr. Albert Ocana

Medical Director, Translational Research Unit, Albacete University Hospital

15+ years experience in oncology research Interest areas includes Breast Cancer, clinical early drug development.

Dr. Mark Drummond

Lead Hematologist, Chief Investigator for Clinical trial, Beatson West of Scotland Cancer Centre

20+ years experience in Medicine & 13 years of experience in blood cancer research
Interest areas includes Acute Chronic Leukemia.

Dr. Jose Ales Martinez

Head Of Oncology, Avila Health Care

20+ years experience in oncology research Interest areas includes Breast Cancer, Colorectal Cancer, Lung Cancer.





Dr. Rosati Gerado

Director Of Oncology, U.O. Oncologia Medica

25+ years experience in oncology research Interest areas includes Metastatic Colorectal Cancer

Dr. Hidetoshi Hayashi

Lecturer Oncology, Kindai University Hospital

15+ years experience in Medicine Interest areas includes Non-Small Cell Lung Cancer.

Dr. Howard West

Medical Director, Swedish Medical Center

20+ years experience in oncology research Interest areas includes Thoracic oncology.

Dr. Phillipe Solal Celigny

Oncology research, Lymphoma Cancer

15+ years experience in oncology research Interest areas includes Lymphoma Cancer.





To explore how Growth+Onco can add custom value to your team’s output, please feel free to reach out to either Rishabh or Moneypreet!

Rishabh Bhawsar

Director- Client Solutions

Money Preet Kaur

Associate Director (Growth + )